April 9, 2026 — The global clinical treatment equipment market is experiencing a period of profound transformation, driven by advancing intelligent technologies, the rising trend of localization, strong policy support, and growing demand for precise, efficient medical services. According to the latest industry report from QYResearch, the global market size reached USD 556.22 billion in 2025 and is expected to hit USD 582.90 billion in 2026, with a compound annual growth rate (CAGR) of 5.2% from 2026 to 2032, ultimately reaching USD 788.31 billion by 2032. This growth is underpinned by aging populations, increasing prevalence of chronic diseases, and the continuous integration of AI, IoT, and other advanced technologies into clinical equipment.
A key trend reshaping the market in 2026 is the deep integration of artificial intelligence (AI), which has evolved from an auxiliary tool to a core component of clinical treatment equipment. By the end of 2025, a total of 207 AI medical devices had obtained Class III medical device registration certificates globally, with 41 new approvals in 2025 alone, reflecting strong regulatory support for AI-driven medical innovation. In diagnostic imaging, AI algorithms are now embedded in the imaging process, adjusting scanning parameters in real-time based on patient characteristics to achieve high-definition imaging with minimal radiation dose—reducing CT radiation to 1/10 of traditional levels in some cases. For example, a domestically developed whole-body PET/CT named "Explorer" has shortened scanning time from over 20 minutes to as fast as 30 seconds, while enabling 4D dynamic imaging to track drug metabolism.
Localization has become an irreversible trend in the clinical treatment equipment market, shifting from policy encouragement to market-driven choice. Governments worldwide are strengthening support for domestic equipment manufacturers to ensure supply chain security, with China taking the lead in implementing strict localization requirements—mandating that core components of medical equipment have a localization rate of over 90% for public hospital procurement. Domestic manufacturers have made remarkable breakthroughs in high-end segments: Neusoft Medical has launched a wide-body CT with leading global rotation speed, while United Imaging’s 5T magnetic resonance imaging (MRI) has reached international advanced levels. In early 2026, domestic CT products achieved an 8.5% growth in bidding volume, and ultrasound equipment saw a 10.9% increase, outperforming the overall market downturn.
Policy support is playing a crucial role in boosting market growth. In 2026, China allocated 93.6 billion yuan in ultra-long-term special bonds to support medical equipment updates, driving over 460 billion yuan in total investment across 4,500 projects. Meanwhile, the National Healthcare Security Administration (NHSA) has issued guidelines to establish a unified national pricing mechanism for innovative equipment such as surgical robots, focusing on their clinical value rather than just equipment costs. This policy adjustment has promoted the rational application of high-end equipment and accelerated the commercialization of innovative technologies.
Technological innovation is also expanding the boundaries of clinical treatment equipment. Minimally invasive surgical robots are evolving toward intelligence and flexibility, with single-port and natural orifice surgical robots gaining traction for their smaller trauma and faster recovery advantages. Soft robots made of flexible materials are being tested for use in narrow anatomical structures such as cerebral blood vessels and bronchi, opening new possibilities for interventional therapy. Additionally, advancements in flexible electronics and degradable biomaterials have improved the biocompatibility of implantable devices, such as pacemakers and nerve stimulators, reducing complications and eliminating the need for secondary surgery in some cases.
Despite robust growth, the market faces challenges including constrained hospital procurement budgets and high R&D costs. While policy funds support equipment updates, many medical institutions still face funding pressures, leading to a short-term decline in bidding volume for some equipment categories—such as a 25.6% drop in CT and 20.1% drop in surgical robot bids in January 2026. However, the long-term outlook remains positive, as ongoing technological breakthroughs, expanding application scenarios, and growing demand for precision medicine are expected to offset these hurdles. Looking ahead, the clinical treatment equipment market will continue to evolve toward intelligence, localization, and miniaturization, empowering the transformation of global healthcare toward more efficient, precise, and accessible services.